ClinicalTrials.gg
CompletedNCT04754594Updated Dec 6, 2024Results posted

To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older

A Phase 2/3 interventional study of BNT162b2 and Placebo in SARS-CoV-2 Infection, COVID-19 and Maternal Immunization, sponsored by BioNTech SE. Completed at 90 sites in 5 countries. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-06.

Sponsored by BioNTech SE · Phase 2/3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
726
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.

Enrollment
20th of 54
726 · median 575
Started
2021
with 29 others
Phase 2/3
5 of 54
none open now
Registered
7th of 54
by date
Lead sponsor
20 of 54
BioNTech SE

Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 20th largest by enrollment, is one of 30 that started in 2021, is one of 5 in phase 2/3, and was the 7th registered.

COVID-19

7,993 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About BNT162 Vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing BNT162 Vaccine in COVID-19, or all of them as a file.
02

Study summary

Results will be submitted, however please note that data are not yet available for all serology outcome measures.

This will be a Phase 2/3, randomized, placebo-controlled, observer-blind study evaluating the safety, tolerability, and immunogenicity of 30 µg of BNT162b2 or placebo administered in 2 doses, 21 days apart, in approximately 350 healthy pregnant women 18 years of age or older vaccinated at 24 to 34 weeks' gestation. Participants will be randomized 1:1 to receive BNT162b2 or placebo (saline).

Read the detailed description

The Phase 2 portion of the study will include approximately 200 pregnant women randomized 1:1 to receive BNT162b2 or placebo (saline) at 27 to 34 weeks' gestation. IRC review of safety data through 7 days after the second dose for all Phase 2 participants will be completed.

The Phase 3 portion of this study will assess the safety, tolerability, and immunogenicity of BNT162b2 among pregnant women enrolled at 24 to 34 weeks' gestation.

Maternal participants who originally received placebo will receive BNT162b2 at defined time points as part of the study.

03

Conditions studied

  • SARS-CoV-2 Infection
  • COVID-19
  • Maternal Immunization

Browse trials for

Keywords

  • SARS-CoV-2 Infection
  • COVID-19
  • Maternal Immunization
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy women ≥18 years of age who are between 24 0/7 and 34 0/7 weeks' gestation on the day of planned vaccination, with an uncomplicated, singleton pregnancy, who are at no known increased risk for complications.
  2. Participants who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  3. Healthy participants who are determined by medical history, physical examination, and clinical judgment to be appropriate for inclusion in the study
  4. Documented negative antibody test (Phase 2 only), syphilis test, and surface antigen test during this pregnancy and prior to randomization
  5. Participant is willing to give for her infant to participate in the study
  6. Capable of giving signed informed consent

Exclusion criteria

Exclusion Criteria:

  1. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  2. Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID 19.
  3. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention or any related vaccine.
  4. Participants with known or suspected immunodeficiency.
  5. Bleeding diathesis or condition associated with prolonged bleeding that would in the opinion of the investigator contraindicate intramuscular injection.
  6. Previous vaccination with any coronavirus vaccine.
  7. Receipt of medications intended to prevent COVID 19.
  8. Receipt of blood/plasma products or immunoglobulin, from 60 days before administration of study intervention, or planned receipt through delivery, with 1 exception, anti-D immunoglobulin (eg, RhoGAM), which can be given at any time.
  9. Current alcohol abuse or illicit drug use.
  10. Participants who receive treatment with therapy, including cytotoxic agents or systemic , eg, for cancer or an disease, or planned receipt through the postvaccination blood draw.
  11. Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation.
  12. Previous participation in other studies involving study intervention containing LNPs.
  13. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
  14. Participants whose unborn baby has been fathered by site staff members directly involved in the conduct of the study or their family members, site staff members otherwise supervised by the investigator, or Pfizer employees directly involved in the conduct of the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
726 participants (actual)

Study arms

  • Experimental
    BNT162b2

    2 doses

    Biological: BNT162b2

  • Placebo comparator
    Placebo

    2 doses

    Other: Placebo

Interventions

  • BiologicalBNT162b2

    Intramuscular Injection

  • OtherPlacebo

    Intramuscular Injection

06

What researchers measure

Primary outcomes

  1. Percentage of Maternal Participants Reporting Local Reactions Within 7 Days After Dose 1

    Pain at injection site, redness \& swelling were recorded by participants in an electronic diary (e-diary). Redness \& swelling were measured \& recorded in measuring devise units (range 1 to 21) then converted to cm. 1 measuring device unit = 0.5 cm \& graded as mild: \> 2.0 to 5.0 cm, moderate: \> 5.0 to 10.0 cm, severe: \> 10.0 cm, grade 4 (potentially life threatening): necrosis or exfoliative dermatitis (redness) \& necrosis (swelling). Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity \& grade 4 (potentially life threatening): emergency room visit or hospitalization for severe pain. Grade 4 reactions were classified by the investigator or medically qualified person. Reactions reported as adverse events in the case report form within 7 days after the study vaccination were also included in the analysis. Exact 2-sided 95% confidence interval (CI) was based on Clopper \& Pearson method.

    Time frame: From Day 1 to Day 7 after dose 1

  2. Percentage of Maternal Participants Reporting Local Reactions Within 7 Days After Dose 2

    Pain at injection site, redness \& swelling were recorded by participants in an e-diary. Redness \& swelling were measured \& recorded in measuring devise units (range 1 to 21) then converted to cm. 1 measuring device unit = 0.5 cm \& graded as mild: \> 2.0 to 5.0 cm, moderate: \> 5.0 to 10.0 cm, severe: \> 10.0 cm, grade 4 (potentially life threatening): necrosis or exfoliative dermatitis (redness) \& necrosis (swelling). Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity \& grade 4 (potentially life threatening): emergency room visit or hospitalization for severe pain. Grade 4 reactions were classified by the investigator or medically qualified person. Reactions reported as adverse events (AEs) in the case report form (CRF) within 7 days after the study vaccination were also included in the analysis. Exact 2-sided 95% CI was based on the Clopper \& Pearson method.

    Time frame: From Day 1 to Day 7 after dose 2

  3. Percentage of Maternal Participants Reporting Systemic Events Within 7 Days After Dose 1

    Systemic events were recorded by participants in an e-diary. Fever was oral temperature \>= 38 degree Celsius (°C) \& categorized as \>=38.0 to 38.4 °C, \>38.4 to 38.9 °C, \>38.9 to 40.0 °C \& \>40.0 °C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain were graded mild: did not interfere with activity, moderate: some interference with activity \& severe: prevented daily routine activity. Vomiting was graded mild: 1 to 2 times in 24 hours (h), moderate: \>2 times in 24h \& severe: required intravenous hydration. Diarrhea was graded mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h \& severe: 6 or more loose stools in 24h. For all systemic events except fever, Grade 4= emergency room visit or hospitalization. Grade 4 events were classified by the investigator/medically qualified person. Systemic events reported as AEs in the CRF within 7 days after vaccination were also included in analysis. Exact 95% CI was based on Clopper \& Pearson method.

    Time frame: From Day 1 to Day 7 after dose 1

  4. Percentage of Maternal Participants Reporting Systemic Events Within 7 Days After Dose 2

    Systemic events were recorded by participants in an e-diary. Fever was oral temperature \>= 38 °C \& categorized as \>=38.0 to 38.4 °C, \>38.4 to 38.9 °C, \>38.9 to 40.0 °C \& \>40.0 °C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain were graded mild: did not interfere with activity, moderate: some interference with activity \& severe: prevented daily routine activity. Vomiting was graded mild: 1 to 2 times in 24 h, moderate: \>2 times in 24 h \& severe: required intravenous hydration. Diarrhea was graded mild: 2 to 3 loose stools in 24 h, moderate: 4 to 5 loose stools in 24 h \& severe: 6 or more loose stools in 24 h. For all systemic events except fever, Grade 4= emergency room visit or hospitalization. Grade 4 events were classified by the investigator/medically qualified person. Systemic events reported as AEs in the CRF within 7 days after vaccination were also included in analysis. Exact 95% CI was based on Clopper \& Pearson method.

    Time frame: From Day 1 to Day 7 after dose 2

  5. Percentage of Maternal Participants With Adverse Events (AEs) From Dose 1 Through 1 Month After Dose 2 - Blinded Follow-up Period

    An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided 95% CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From dose 1 on Day 1 through 1 month after dose 2 (approximately 2 months)

  6. Percentage of Maternal Participants Reporting Serious Adverse Events (SAEs) From Dose 1 Through 1 Month After Delivery - Blinded Follow-up Period

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: From dose 1 on Day 1 through 1 month after delivery (up to 22 weeks)

  7. Geometric Mean Ratio (GMR) of the SARS-CoV-2 Neutralizing Titers in Pregnant Women to Those in Nonpregnant Women From Study C4591001 (NCT04368728) for Evaluable Immunogenicity Population Without Evidence of Prior SARS-CoV-2 Infection

    GMR of SARS-CoV-2 neutralizing titers in pregnant women to those in nonpregnant women from study C4591001 (NCT04368728) for evaluable immunogenicity population without evidence of prior SARS-CoV-2 infection up to 1 month after Dose 2 was reported in this outcome measure. Geometric mean titer (GMT) and 2-sided 95% CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on student t distribution) and was reported in descriptive section. GMR was reported in statistical analysis section of this outcome measure. Evaluable immunogenicity population included all participants who were eligible and randomized, received 2 doses of vaccine to which they were randomized, with Dose 2 received within predefined window (19-42 days, inclusive, after Dose 1); had at least 1 valid immunogenicity result within an appropriate window 1 month after Dose 2 (28-42 days, inclusive, after Dose 2); and had no other important protocol deviations as determined by the clinician.

    Time frame: 1 Month after Dose 2

  8. GMR of SARS-CoV-2 Neutralizing Titers in Pregnant Women to Those in Nonpregnant Women From Study C4591001 (NCT04368728) for Evaluable Immunogenicity Population With and Without Evidence of Prior SARS-CoV-2 Infection

    GMR of SARS-CoV-2 neutralizing titers in pregnant women to those in nonpregnant women from study C4591001 (NCT04368728) for evaluable immunogenicity population with and without evidence of prior SARS-CoV-2 infection was reported in this outcome measure. GMT and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the student t distribution) and was reported in the descriptive section. GMR was reported in the statistical analysis section. Evaluable immunogenicity population included all participants who were eligible and randomized, received 2 doses of the vaccine to which they were randomized, with Dose 2 received within the predefined window (19-42 days, inclusive, after Dose 1); had at least 1 valid immunogenicity result within an appropriate window 1 month after Dose 2 (28-42 days, inclusive, after Dose 2); and had no other important protocol deviations as determined by the clinician.

    Time frame: 1 Month after Dose 2

Secondary outcomes

  1. COVID-19 Incidence Per 100 Person-Years of Blinded Follow up in Evaluable Maternal Participants Without Evidence of Prior SARS-CoV-2 Infection

    COVID-19 incidence per 100 person-years of blinded follow-up in evaluable maternal participants without evidence of prior SARS-CoV-2 infection prior to 7 days after receipt of Dose 2 was reported in this outcome measure.

    Time frame: From 7 days after Dose 2 up to 1 month after delivery (Surveillance time [100 person-year]: BNT162b2- 0.155, Placebo- 0.149)

  2. COVID-19 Incidence Per 100 Person-Years of Blinded Follow up in Evaluable Maternal Participants With or Without Evidence of Prior SARS-CoV-2 Infection

    COVID-19 incidence per 100 person-years of blinded follow-up in evaluable maternal participants with or without evidence of prior SARS-CoV-2 infection was reported in this outcome measure.

    Time frame: From 7 days after Dose 2 up to 1 month after delivery (Surveillance time [100 person-year]: BNT162b2- 0.270, Placebo- 0.263)

  3. Incidence of Asymptomatic Infection of SARS-CoV-2 Through 1 Month After Delivery in Evaluable Maternal Participants Without Evidence of Prior SARS-CoV-2 Infection

    Incidence of asymptomatic infection of SARS-CoV-2 through 1 month after delivery in evaluable maternal participants without evidence of prior SARS-CoV-2 infection prior to the first post-dose 2 N-binding test was reported in this outcome measure.

    Time frame: Up to 1 month after delivery (Surveillance time [100 person-year]: BNT162b2- 0.099, Placebo- 0.147)

  4. Geometric Mean Concentration (GMCs) of Full-Length S-Binding Immunoglobulin G (IgG) Levels in Evaluable Maternal Participants

    GMCs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMCs of full-length S-binding IgG levels in evaluable maternal participants at baseline, 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery was reported in this outcome measure. Evaluable immunogenicity population included all participants who were eligible and randomized, received 2 doses of the vaccine to which they were randomized, with Dose 2 received within the predefined window (19-42 days, inclusive, after Dose 1); had at least 1 valid immunogenicity result within an appropriate window 1 month after Dose 2 (28-42 days, inclusive, after Dose 2); and had no other important protocol deviations as determined by the clinician.

    Time frame: Baseline (before Dose 1), 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery

  5. Geometric Mean Titer (GMTs) of SARS-CoV-2 Neutralizing Titers in Evaluable Maternal Participants

    GMTs, and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMTs of SARS-CoV-2 neutralizing titers in evaluable maternal participants at baseline, 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery was reported in this outcome measure. Evaluable immunogenicity population included all participants who were eligible and randomized, received 2 doses of the vaccine to which they were randomized, with Dose 2 received within the predefined window (19-42 days, inclusive, after Dose 1); had at least 1 valid immunogenicity result within an appropriate window 1 month after Dose 2 (28-42 days, inclusive, after Dose 2); and had no other important protocol deviations as determined by the clinician.

    Time frame: Baseline (before Dose 1), 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery

  6. Geometric Mean Fold Rise (GMFR) From Before Vaccination to Each Subsequent Time Point After Vaccination for Full-Length S-Binding IgG Levels in Evaluable Maternal Participants

    GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMFR from before vaccination to each subsequent time point after vaccination for full-length S-binding IgG levels in evaluable maternal participants at 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery was reported in this outcome measure. Evaluable immunogenicity population included all participants who were eligible and randomized, received 2 doses of the vaccine to which they were randomized, with Dose 2 received within the predefined window (19-42 days, inclusive, after Dose 1); had at least 1 valid immunogenicity result within an appropriate window 1 month after Dose 2 (28-42 days, inclusive, after Dose 2); and had no other important protocol deviations as determined by the clinician.

    Time frame: From before dose 1 up to 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery

  7. Geometric Mean Fold Rise (GMFR) From Before Vaccination to Each Subsequent Time Point After Vaccination for SARS-CoV-2 Neutralizing Titers in Evaluable Maternal Participants

    GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMFR from before vaccination to each subsequent time point after vaccination for SARS-CoV-2 neutralizing titers in evaluable maternal participants at 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery was reported in this outcome measure. Evaluable immunogenicity population included all participants who were eligible and randomized, received 2 doses of the vaccine to which they were randomized, with Dose 2 received within the predefined window (19-42 days, inclusive, after Dose 1); had at least 1 valid immunogenicity result within an appropriate window 1 month after Dose 2 (28-42 days, inclusive, after Dose 2); and had no other important protocol deviations as determined by the clinician.

    Time frame: From before dose 1 up to 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery

  8. Percentage of Infant Participants Reporting Specific Birth Outcomes

    Percentage of infant participants reporting specific birth outcomes (normal, congenital malformation/anomaly, other neonatal problems) were reported in this outcome measure.

    Time frame: At birth

  9. Percentage of Infant Participants Reporting Adverse Events From Birth Through 1 Month of Age

    An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: From birth through 1 month of age

  10. Percentage of Infant Participants Reporting Serious Adverse Events (SAE) From Birth Through 6 Months of Age

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: From birth through 6 months of age

  11. Percentage of Infant Participants Reporting Adverse Event of Special Interest (AESI) From Birth Through 6 Months of Age

    Percentage of infant participants who reported AESI including major congenital anomalies and developmental delay from birth through 6 months of age were reported in this outcome measure. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: From birth through 6 months of age

  12. GMCs of Full-Length S-Binding IgG Levels at Birth and 6 Months of Age in Infant Participants Born to Evaluable Maternal Participants

    GMCs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMCs of full-length S-binding IgG levels at birth and 6 months of age in infant participants born to evaluable maternal participants was reported in this outcome measure.

    Time frame: At birth and 6 months of age

  13. GMFR of Full-Length S-Binding IgG Levels From Birth to 6 Months of Age in Infant Participants Born to Evaluable Maternal Participants

    GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMFR of full-length S-binding IgG levels from birth to 6 months of age in infant participants born to evaluable maternal participants was reported in this outcome measure.

    Time frame: From birth to 6 months of age

07

Results

Posted Dec 6, 2024

Participant flow

This study was conducted in 2 periods-Blinded Period (from Day 1 to 1 month post-delivery) and Unblinded Period (1 to 6 Months Post-Delivery for those maternal participants who initially received BNT162b2 and from first dose of BNT162b2 to 1 month after second dose of BNT162b2 for those maternal participants who initially received placebo).

Blinded Period
Participant flow — Blinded Period
MilestoneMaternal Participants: BNT162b2 30 mcgMaternal Participants: Placebo Then BNT162b2 30 mcgInfant Participants: BNT162b2 30 mcgInfant Participants: Placebo
Started17417400
Vaccination 117317300
Vaccination 217017000
Completed16115900
Not completed131500
Withdrew: Withdrawal by subject4900
Withdrew: Protocol violation2200
Withdrew: Lost to follow-up1100
Withdrew: Unblinded before 1-month postdelivery visit6300
Unblinded Period
Participant flow — Unblinded Period
MilestoneMaternal Participants: BNT162b2 30 mcgMaternal Participants: Placebo Then BNT162b2 30 mcgInfant Participants: BNT162b2 30 mcgInfant Participants: Placebo
Started16716200
Vaccination 3015200
Vaccination 4014800
Completed15114700
Not completed161500
Withdrew: Withdrawal by subject6800
Withdrew: Lost to follow-up5300
Withdrew: Protocol violation2400
Withdrew: Other3000
Infant Participants
Participant flow — Infant Participants
MilestoneMaternal Participants: BNT162b2 30 mcgMaternal Participants: Placebo Then BNT162b2 30 mcgInfant Participants: BNT162b2 30 mcgInfant Participants: Placebo
Started00167168
Completed00152139
Not completed001529
Withdrew: Withdrawal by subject00917
Withdrew: Lost to follow-up00410
Withdrew: Death0011
Withdrew: Other0011

Outcome measures

PrimaryPercentage of Maternal Participants Reporting Local Reactions Within 7 Days After Dose 1

Pain at injection site, redness \& swelling were recorded by participants in an electronic diary (e-diary). Redness \& swelling were measured \& recorded in measuring devise units (range 1 to 21) then converted to cm. 1 measuring device unit = 0.5 cm \& graded as mild: \> 2.0 to 5.0 cm, moderate: \> 5.0 to 10.0 cm, severe: \> 10.0 cm, grade 4 (potentially life threatening): necrosis or exfoliative dermatitis (redness) \& necrosis (swelling). Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity \& grade 4 (potentially life threatening): emergency room visit or hospitalization for severe pain. Grade 4 reactions were classified by the investigator or medically qualified person. Reactions reported as adverse events in the case report form within 7 days after the study vaccination were also included in the analysis. Exact 2-sided 95% confidence interval (CI) was based on Clopper \& Pearson method.

Time frame:
From Day 1 to Day 7 after dose 1
Reported as:
Number · Percentage of participants
Percentage of Maternal Participants Reporting Local Reactions Within 7 Days After Dose 1
Percentage of participantsMaternal Participants: BNT162b2 30 mcgMaternal Participants: Placebo
Redness: Mild2.5 (0.7 to 6.2)0.6 (0.0 to 3.4)
Redness: Moderate0.6 (0.0 to 3.4)0 (0.0 to 2.2)
Redness: Severe0 (0.0 to 2.3)0 (0.0 to 2.2)
Redness: Grade 40 (0.0 to 2.3)0 (0.0 to 2.2)
Swelling: Mild4.3 (1.8 to 8.8)0 (0.0 to 2.2)
Swelling: Moderate0.6 (0.0 to 3.4)0 (0.0 to 2.2)
Swelling: Severe0.6 (0.0 to 3.4)0 (0.0 to 2.2)
Swelling: Grade 40 (0.0 to 2.3)0 (0.0 to 2.2)
Pain at the injection site: Mild59.0 (51.0 to 66.7)9.8 (5.7 to 15.5)
Pain at the injection site: Moderate23.6 (17.3 to 30.9)0 (0.0 to 2.2)
Pain at the injection site: Severe0 (0.0 to 2.3)0 (0.0 to 2.2)
Pain at the injection site: Grade 40 (0.0 to 2.3)0 (0.0 to 2.2)
PrimaryPercentage of Maternal Participants Reporting Local Reactions Within 7 Days After Dose 2

Pain at injection site, redness \& swelling were recorded by participants in an e-diary. Redness \& swelling were measured \& recorded in measuring devise units (range 1 to 21) then converted to cm. 1 measuring device unit = 0.5 cm \& graded as mild: \> 2.0 to 5.0 cm, moderate: \> 5.0 to 10.0 cm, severe: \> 10.0 cm, grade 4 (potentially life threatening): necrosis or exfoliative dermatitis (redness) \& necrosis (swelling). Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity \& grade 4 (potentially life threatening): emergency room visit or hospitalization for severe pain. Grade 4 reactions were classified by the investigator or medically qualified person. Reactions reported as adverse events (AEs) in the case report form (CRF) within 7 days after the study vaccination were also included in the analysis. Exact 2-sided 95% CI was based on the Clopper \& Pearson method.

Time frame:
From Day 1 to Day 7 after dose 2
Reported as:
Number · Percentage of participants
Percentage of Maternal Participants Reporting Local Reactions Within 7 Days After Dose 2
Percentage of participantsMaternal Participants: BNT162b2 30 mcgMaternal Participants: Placebo
Redness: Mild3.4 (1.1 to 7.7)0 (0.0 to 2.5)
Redness: Moderate2.0 (0.4 to 5.8)0 (0.0 to 2.5)
Redness: Severe0 (0.0 to 2.5)0 (0.0 to 2.5)
Redness: Grade 40 (0.0 to 2.5)0 (0.0 to 2.5)
Swelling: Mild4.1 (1.5 to 8.6)0.7 (0.0 to 3.8)
Swelling: Moderate2.7 (0.7 to 6.8)0 (0.0 to 2.5)
Swelling: Severe0 (0.0 to 2.5)0 (0.0 to 2.5)
Swelling: Grade 40 (0.0 to 2.5)0 (0.0 to 2.5)
Pain at the injection site: Mild54.7 (46.3 to 62.9)12.3 (7.5 to 18.8)
Pain at the injection site: Moderate19.6 (13.5 to 26.9)4.1 (1.5 to 8.7)
Pain at the injection site: Severe0.7 (0.0 to 3.7)0 (0.0 to 2.5)
Pain at the injection site: Grade 40 (0.0 to 2.5)0 (0.0 to 2.5)
PrimaryPercentage of Maternal Participants Reporting Systemic Events Within 7 Days After Dose 1

Systemic events were recorded by participants in an e-diary. Fever was oral temperature \>= 38 degree Celsius (°C) \& categorized as \>=38.0 to 38.4 °C, \>38.4 to 38.9 °C, \>38.9 to 40.0 °C \& \>40.0 °C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain were graded mild: did not interfere with activity, moderate: some interference with activity \& severe: prevented daily routine activity. Vomiting was graded mild: 1 to 2 times in 24 hours (h), moderate: \>2 times in 24h \& severe: required intravenous hydration. Diarrhea was graded mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h \& severe: 6 or more loose stools in 24h. For all systemic events except fever, Grade 4= emergency room visit or hospitalization. Grade 4 events were classified by the investigator/medically qualified person. Systemic events reported as AEs in the CRF within 7 days after vaccination were also included in analysis. Exact 95% CI was based on Clopper \& Pearson method.

Time frame:
From Day 1 to Day 7 after dose 1
Reported as:
Number · Percentage of participants
Percentage of Maternal Participants Reporting Systemic Events Within 7 Days After Dose 1
Percentage of participantsMaternal Participants: BNT162b2 30 mcgMaternal Participants: Placebo
Fever: >=38.0 to 38.4 deg C (100.4 to 101.1 deg Fahrenheit [F])0.6 (0.0 to 3.4)1.2 (0.1 to 4.4)
Fever: >38.4 to 38.9 deg C (101.2 to 102.0 deg F)0 (0.0 to 2.3)0 (0.0 to 2.2)
Fever: >38.9 to 40.0 deg C (102.1 to 104.0 deg F)0.6 (0.0 to 3.4)0.6 (0.0 to 3.4)
Fever: >40 deg C (>104.0 deg F)0 (0.0 to 2.3)0 (0.0 to 2.2)
Fatigue/tiredness: Mild26.1 (19.5 to 33.6)20.9 (14.9 to 27.9)
Fatigue/tiredness: Moderate23.0 (16.7 to 30.3)21.5 (15.4 to 28.6)
Fatigue/tiredness: Severe0.6 (0.0 to 3.4)0.6 (0.0 to 3.4)
Fatigue/tiredness: Grade 40 (0.0 to 2.3)0 (0.0 to 2.2)
Headache: Mild20.5 (14.5 to 27.6)22.1 (16.0 to 29.2)
Headache: Moderate11.8 (7.3 to 17.8)12.9 (8.2 to 19.0)
Headache: Severe1.9 (0.4 to 5.3)0.6 (0.0 to 3.4)
Headache: Grade 40 (0.0 to 2.3)0 (0.0 to 2.2)
Chills: Mild5.0 (2.2 to 9.6)5.5 (2.6 to 10.2)
Chills: Moderate1.9 (0.4 to 5.3)0 (0.0 to 2.2)
Chills: Severe0 (0.0 to 2.3)0 (0.0 to 2.2)
Chills: Grade 40 (0.0 to 2.3)0 (0.0 to 2.2)
Vomiting: Mild5.0 (2.2 to 9.6)6.1 (3.0 to 11.0)
Vomiting: Moderate0 (0.0 to 2.3)3.1 (1.0 to 7.0)
Vomiting: Severe0 (0.0 to 2.3)0 (0.0 to 2.2)
Vomiting: Grade 40 (0.0 to 2.3)0 (0.0 to 2.2)
Diarrhea: Mild11.2 (6.8 to 17.1)7.4 (3.9 to 12.5)
Diarrhea: Moderate0.6 (0.0 to 3.4)1.2 (0.1 to 4.4)
Diarrhea: Severe0 (0.0 to 2.3)0 (0.0 to 2.2)
Diarrhea: Grade 40 (0.0 to 2.3)0 (0.0 to 2.2)
New or worsened muscle pain: Mild6.8 (3.5 to 11.9)6.1 (3.0 to 11.0)
New or worsened muscle pain: Moderate5.6 (2.6 to 10.3)5.5 (2.6 to 10.2)
New or worsened muscle pain: Severe0 (0.0 to 2.3)0 (0.0 to 2.2)
New or worsened muscle pain: Grade 40 (0.0 to 2.3)0 (0.0 to 2.2)
New or worsened joint pain: Mild1.2 (0.2 to 4.4)2.5 (0.7 to 6.2)
New or worsened joint pain: Moderate1.9 (0.4 to 5.3)2.5 (0.7 to 6.2)
New or worsened joint pain: Severe0 (0.0 to 2.3)0 (0.0 to 2.2)
New or worsened joint pain: Grade 40 (0.0 to 2.3)0 (0.0 to 2.2)
PrimaryPercentage of Maternal Participants Reporting Systemic Events Within 7 Days After Dose 2

Systemic events were recorded by participants in an e-diary. Fever was oral temperature \>= 38 °C \& categorized as \>=38.0 to 38.4 °C, \>38.4 to 38.9 °C, \>38.9 to 40.0 °C \& \>40.0 °C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain were graded mild: did not interfere with activity, moderate: some interference with activity \& severe: prevented daily routine activity. Vomiting was graded mild: 1 to 2 times in 24 h, moderate: \>2 times in 24 h \& severe: required intravenous hydration. Diarrhea was graded mild: 2 to 3 loose stools in 24 h, moderate: 4 to 5 loose stools in 24 h \& severe: 6 or more loose stools in 24 h. For all systemic events except fever, Grade 4= emergency room visit or hospitalization. Grade 4 events were classified by the investigator/medically qualified person. Systemic events reported as AEs in the CRF within 7 days after vaccination were also included in analysis. Exact 95% CI was based on Clopper \& Pearson method.

Time frame:
From Day 1 to Day 7 after dose 2
Reported as:
Number · Percentage of participants
Percentage of Maternal Participants Reporting Systemic Events Within 7 Days After Dose 2
Percentage of participantsMaternal Participants: BNT162b2 30 mcgMaternal Participants: Placebo
Fever: >=38.0 to 38.4 deg C (100.4 to 101.1 deg F)1.4 (0.2 to 4.8)0.7 (0.0 to 3.8)
Fever: >38.4 to 38.9 deg C (101.2 to 102.0 deg F)0.7 (0.0 to 3.7)0 (0.0 to 2.5)
Fever: >38.9 to 40.0 deg C (102.1 to 104.0 deg F)0 (0.0 to 2.5)0 (0.0 to 2.5)
Fever: >40 deg C (>104.0 deg F)0 (0.0 to 2.5)0 (0.0 to 2.5)
Fatigue/tiredness: Mild15.5 (10.1 to 22.4)15.8 (10.3 to 22.7)
Fatigue/tiredness: Moderate32.4 (25.0 to 40.6)18.5 (12.6 to 25.8)
Fatigue/tiredness: Severe2.0 (0.4 to 5.8)0 (0.0 to 2.5)
Fatigue/tiredness: Grade 40 (0.0 to 2.5)0 (0.0 to 2.5)
Headache: Mild25.0 (18.3 to 32.8)13.7 (8.6 to 20.4)
Headache: Moderate14.9 (9.6 to 21.6)10.3 (5.9 to 16.4)
Headache: Severe1.4 (0.2 to 4.8)0 (0.0 to 2.5)
Headache: Grade 40 (0.0 to 2.5)0 (0.0 to 2.5)
Chills: Mild4.7 (1.9 to 9.5)0.7 (0.0 to 3.8)
Chills: Moderate7.4 (3.8 to 12.9)0 (0.0 to 2.5)
Chills: Severe0.7 (0.0 to 3.7)0 (0.0 to 2.5)
Chills: Grade 40 (0.0 to 2.5)0 (0.0 to 2.5)
Vomiting: Mild8.8 (4.8 to 14.6)2.1 (0.4 to 5.9)
Vomiting: Moderate0 (0.0 to 2.5)1.4 (0.2 to 4.9)
Vomiting: Severe0 (0.0 to 2.5)0 (0.0 to 2.5)
Vomiting: Grade 40 (0.0 to 2.5)0 (0.0 to 2.5)
Diarrhea: Mild6.1 (2.8 to 11.2)4.1 (1.5 to 8.7)
Diarrhea: Moderate0 (0.0 to 2.5)1.4 (0.2 to 4.9)
Diarrhea: Severe0 (0.0 to 2.5)0 (0.0 to 2.5)
Diarrhea: Grade 40 (0.0 to 2.5)0 (0.0 to 2.5)
New or worsened muscle pain: Mild13.5 (8.5 to 20.1)4.8 (1.9 to 9.6)
New or worsened muscle pain: Moderate12.8 (7.9 to 19.3)2.1 (0.4 to 5.9)
New or worsened muscle pain: Severe0.7 (0.0 to 3.7)0 (0.0 to 2.5)
New or worsened muscle pain: Grade 40 (0.0 to 2.5)0 (0.0 to 2.5)
New or worsened joint pain: Mild7.4 (3.8 to 12.9)4.8 (1.9 to 9.6)
New or worsened joint pain: Moderate6.1 (2.8 to 11.2)1.4 (0.2 to 4.9)
New or worsened joint pain: Severe0 (0.0 to 2.5)0 (0.0 to 2.5)
New or worsened joint pain: Grade 40 (0.0 to 2.5)0 (0.0 to 2.5)
PrimaryPercentage of Maternal Participants With Adverse Events (AEs) From Dose 1 Through 1 Month After Dose 2 - Blinded Follow-up Period

An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided 95% CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From dose 1 on Day 1 through 1 month after dose 2 (approximately 2 months)
Reported as:
Number · Percentage of participants
Percentage of Maternal Participants With Adverse Events (AEs) From Dose 1 Through 1 Month After Dose 2 - Blinded Follow-up Period
Percentage of participantsMaternal Participants: BNT162b2 30 mcgMaternal Participants: Placebo
Percentage of Maternal Participants With Adverse Events (AEs) From Dose 1 Through 1 Month After Dose 2 - Blinded Follow-up Period23.6 (17.3 to 30.9)22.7 (16.5 to 29.9)
PrimaryPercentage of Maternal Participants Reporting Serious Adverse Events (SAEs) From Dose 1 Through 1 Month After Delivery - Blinded Follow-up Period

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
From dose 1 on Day 1 through 1 month after delivery (up to 22 weeks)
Reported as:
Number · Percentage of participants
Percentage of Maternal Participants Reporting Serious Adverse Events (SAEs) From Dose 1 Through 1 Month After Delivery - Blinded Follow-up Period
Percentage of participantsMaternal Participants: BNT162b2 30 mcgMaternal Participants: Placebo
Percentage of Maternal Participants Reporting Serious Adverse Events (SAEs) From Dose 1 Through 1 Month After Delivery - Blinded Follow-up Period13.0 (8.3 to 19.2)14.1 (9.2 to 20.4)
PrimaryGeometric Mean Ratio (GMR) of the SARS-CoV-2 Neutralizing Titers in Pregnant Women to Those in Nonpregnant Women From Study C4591001 (NCT04368728) for Evaluable Immunogenicity Population Without Evidence of Prior SARS-CoV-2 Infection

GMR of SARS-CoV-2 neutralizing titers in pregnant women to those in nonpregnant women from study C4591001 (NCT04368728) for evaluable immunogenicity population without evidence of prior SARS-CoV-2 infection up to 1 month after Dose 2 was reported in this outcome measure. Geometric mean titer (GMT) and 2-sided 95% CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on student t distribution) and was reported in descriptive section. GMR was reported in statistical analysis section of this outcome measure. Evaluable immunogenicity population included all participants who were eligible and randomized, received 2 doses of vaccine to which they were randomized, with Dose 2 received within predefined window (19-42 days, inclusive, after Dose 1); had at least 1 valid immunogenicity result within an appropriate window 1 month after Dose 2 (28-42 days, inclusive, after Dose 2); and had no other important protocol deviations as determined by the clinician.

Time frame:
1 Month after Dose 2
Reported as:
Geometric mean · Titer
Geometric Mean Ratio (GMR) of the SARS-CoV-2 Neutralizing Titers in Pregnant Women to Those in Nonpregnant Women From Study C4591001 (NCT04368728) for Evaluable Immunogenicity Population Without Evidence of Prior SARS-CoV-2 Infection
TiterMaternal Participants: BNT162b2 30 mcgNon-Pregnant Participants: Study C4591001
Geometric Mean Ratio (GMR) of the SARS-CoV-2 Neutralizing Titers in Pregnant Women to Those in Nonpregnant Women From Study C4591001 (NCT04368728) for Evaluable Immunogenicity Population Without Evidence of Prior SARS-CoV-2 Infection1109.2 (849.2 to 1448.9)1663.7 (1411.5 to 1960.8)
Statistical analysis
  • Maternal Participants: BNT162b2 30 mcg vs Non-Pregnant Participants: Study C4591001 · Geometric mean ratio: 0.67 · 95% CI 0.50 to 0.90
PrimaryGMR of SARS-CoV-2 Neutralizing Titers in Pregnant Women to Those in Nonpregnant Women From Study C4591001 (NCT04368728) for Evaluable Immunogenicity Population With and Without Evidence of Prior SARS-CoV-2 Infection

GMR of SARS-CoV-2 neutralizing titers in pregnant women to those in nonpregnant women from study C4591001 (NCT04368728) for evaluable immunogenicity population with and without evidence of prior SARS-CoV-2 infection was reported in this outcome measure. GMT and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the student t distribution) and was reported in the descriptive section. GMR was reported in the statistical analysis section. Evaluable immunogenicity population included all participants who were eligible and randomized, received 2 doses of the vaccine to which they were randomized, with Dose 2 received within the predefined window (19-42 days, inclusive, after Dose 1); had at least 1 valid immunogenicity result within an appropriate window 1 month after Dose 2 (28-42 days, inclusive, after Dose 2); and had no other important protocol deviations as determined by the clinician.

Time frame:
1 Month after Dose 2
Reported as:
Geometric mean · Titer
GMR of SARS-CoV-2 Neutralizing Titers in Pregnant Women to Those in Nonpregnant Women From Study C4591001 (NCT04368728) for Evaluable Immunogenicity Population With and Without Evidence of Prior SARS-CoV-2 Infection
TiterMaternal Participants: BNT162b2 30 mcgNon-Pregnant Participants: Study C4591001
GMR of SARS-CoV-2 Neutralizing Titers in Pregnant Women to Those in Nonpregnant Women From Study C4591001 (NCT04368728) for Evaluable Immunogenicity Population With and Without Evidence of Prior SARS-CoV-2 Infection2198.7 (1618.5 to 2987.0)1732.0 (1469.4 to 2041.5)
Statistical analysis
  • Maternal Participants: BNT162b2 30 mcg vs Non-Pregnant Participants: Study C4591001 · Geometric mean ratio: 1.27 · 95% CI 0.91 to 1.77
  • Maternal Participants: BNT162b2 30 mcg vs Non-Pregnant Participants: Study C4591001 · Geometric mean ratio: 0.95 · 95% CI 0.69 to 1.30
SecondaryCOVID-19 Incidence Per 100 Person-Years of Blinded Follow up in Evaluable Maternal Participants Without Evidence of Prior SARS-CoV-2 Infection

COVID-19 incidence per 100 person-years of blinded follow-up in evaluable maternal participants without evidence of prior SARS-CoV-2 infection prior to 7 days after receipt of Dose 2 was reported in this outcome measure.

Time frame:
From 7 days after Dose 2 up to 1 month after delivery (Surveillance time [100 person-year]: BNT162b2- 0.155, Placebo- 0.149)
Reported as:
Number · Events per 100 person-years
COVID-19 Incidence Per 100 Person-Years of Blinded Follow up in Evaluable Maternal Participants Without Evidence of Prior SARS-CoV-2 Infection
Events per 100 person-yearsMaternal Participants: BNT162b2 30 mcgMaternal Participants: Placebo
COVID-19 Incidence Per 100 Person-Years of Blinded Follow up in Evaluable Maternal Participants Without Evidence of Prior SARS-CoV-2 Infection12.90313.423
Statistical analysis
  • Maternal Participants: BNT162b2 30 mcg vs Maternal Participants: Placebo · Vaccine efficacy: 3.8 · 95% CI -1227.8 to 93.0
SecondaryCOVID-19 Incidence Per 100 Person-Years of Blinded Follow up in Evaluable Maternal Participants With or Without Evidence of Prior SARS-CoV-2 Infection

COVID-19 incidence per 100 person-years of blinded follow-up in evaluable maternal participants with or without evidence of prior SARS-CoV-2 infection was reported in this outcome measure.

Time frame:
From 7 days after Dose 2 up to 1 month after delivery (Surveillance time [100 person-year]: BNT162b2- 0.270, Placebo- 0.263)
Reported as:
Number · Events per 100 person-years
COVID-19 Incidence Per 100 Person-Years of Blinded Follow up in Evaluable Maternal Participants With or Without Evidence of Prior SARS-CoV-2 Infection
Events per 100 person-yearsMaternal Participants: BNT162b2 30 mcgMaternal Participants: Placebo
COVID-19 Incidence Per 100 Person-Years of Blinded Follow up in Evaluable Maternal Participants With or Without Evidence of Prior SARS-CoV-2 Infection7.40711.407
Statistical analysis
  • Maternal Participants: BNT162b2 30 mcg vs Maternal Participants: Placebo · Vaccine efficacy: 35.1 · 95% CI -466.5 to 94.6
SecondaryIncidence of Asymptomatic Infection of SARS-CoV-2 Through 1 Month After Delivery in Evaluable Maternal Participants Without Evidence of Prior SARS-CoV-2 Infection

Incidence of asymptomatic infection of SARS-CoV-2 through 1 month after delivery in evaluable maternal participants without evidence of prior SARS-CoV-2 infection prior to the first post-dose 2 N-binding test was reported in this outcome measure.

Time frame:
Up to 1 month after delivery (Surveillance time [100 person-year]: BNT162b2- 0.099, Placebo- 0.147)
Reported as:
Number · Events per 100 person-years
Incidence of Asymptomatic Infection of SARS-CoV-2 Through 1 Month After Delivery in Evaluable Maternal Participants Without Evidence of Prior SARS-CoV-2 Infection
Events per 100 person-yearsMaternal Participants: BNT162b2 30 mcgMaternal Participants: Placebo
Incidence of Asymptomatic Infection of SARS-CoV-2 Through 1 Month After Delivery in Evaluable Maternal Participants Without Evidence of Prior SARS-CoV-2 Infection40.40468.027
Statistical analysis
  • Maternal Participants: BNT162b2 30 mcg vs Maternal Participants: Placebo · Vaccine efficacy: 40.9 · 95% CI -104.9 to 86.5
SecondaryGeometric Mean Concentration (GMCs) of Full-Length S-Binding Immunoglobulin G (IgG) Levels in Evaluable Maternal Participants

GMCs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMCs of full-length S-binding IgG levels in evaluable maternal participants at baseline, 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery was reported in this outcome measure. Evaluable immunogenicity population included all participants who were eligible and randomized, received 2 doses of the vaccine to which they were randomized, with Dose 2 received within the predefined window (19-42 days, inclusive, after Dose 1); had at least 1 valid immunogenicity result within an appropriate window 1 month after Dose 2 (28-42 days, inclusive, after Dose 2); and had no other important protocol deviations as determined by the clinician.

Time frame:
Baseline (before Dose 1), 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery
Reported as:
Geometric mean · Units/milliliter (U/mL)
Geometric Mean Concentration (GMCs) of Full-Length S-Binding Immunoglobulin G (IgG) Levels in Evaluable Maternal Participants
Units/milliliter (U/mL)Maternal Participants: BNT162b2 30 mcgMaternal Participants: Placebo
Before Dose 12.4 (1.6 to 3.7)2.0 (1.4 to 2.8)
2 weeks after Dose 27802.0 (6273.3 to 9703.2)1.8 (1.1 to 3.1)
1 month after Dose 24281.0 (3234.7 to 5665.7)1.8 (1.1 to 2.9)
At delivery2747.6 (2144.7 to 3520.0)1.7 (1.0 to 3.0)
6 months after delivery1639.4 (780.1 to 3445.4)—
SecondaryGeometric Mean Titer (GMTs) of SARS-CoV-2 Neutralizing Titers in Evaluable Maternal Participants

GMTs, and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMTs of SARS-CoV-2 neutralizing titers in evaluable maternal participants at baseline, 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery was reported in this outcome measure. Evaluable immunogenicity population included all participants who were eligible and randomized, received 2 doses of the vaccine to which they were randomized, with Dose 2 received within the predefined window (19-42 days, inclusive, after Dose 1); had at least 1 valid immunogenicity result within an appropriate window 1 month after Dose 2 (28-42 days, inclusive, after Dose 2); and had no other important protocol deviations as determined by the clinician.

Time frame:
Baseline (before Dose 1), 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery
Reported as:
Geometric mean · Titer
Geometric Mean Titer (GMTs) of SARS-CoV-2 Neutralizing Titers in Evaluable Maternal Participants
TiterMaternal Participants: BNT162b2 30 mcgMaternal Participants: Placebo
Before Dose 147.6 (41.6 to 54.4)43.5 (43.5 to 43.5)
2 weeks after Dose 21991.8 (1456.3 to 2724.1)45.0 (42.0 to 48.3)
1 month after Dose 21212.6 (855.2 to 1719.4)43.5 (43.5 to 43.5)
At delivery695.7 (500.6 to 966.8)43.5 (43.5 to 43.5)
6 months after delivery465.4 (168.6 to 1284.5)—
SecondaryGeometric Mean Fold Rise (GMFR) From Before Vaccination to Each Subsequent Time Point After Vaccination for Full-Length S-Binding IgG Levels in Evaluable Maternal Participants

GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMFR from before vaccination to each subsequent time point after vaccination for full-length S-binding IgG levels in evaluable maternal participants at 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery was reported in this outcome measure. Evaluable immunogenicity population included all participants who were eligible and randomized, received 2 doses of the vaccine to which they were randomized, with Dose 2 received within the predefined window (19-42 days, inclusive, after Dose 1); had at least 1 valid immunogenicity result within an appropriate window 1 month after Dose 2 (28-42 days, inclusive, after Dose 2); and had no other important protocol deviations as determined by the clinician.

Time frame:
From before dose 1 up to 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rise (GMFR) From Before Vaccination to Each Subsequent Time Point After Vaccination for Full-Length S-Binding IgG Levels in Evaluable Maternal Participants
Fold riseMaternal Participants: BNT162b2 30 mcgMaternal Participants: Placebo
2 weeks after Dose 23618.7 (2489.1 to 5260.7)0.9 (0.8 to 1.1)
1 month after Dose 22276.4 (1545.5 to 3352.9)0.9 (0.8 to 1.1)
At delivery1377.6 (948.6 to 2000.5)0.8 (0.6 to 1.0)
6 months after delivery650.3 (279.3 to 1514.3)—
SecondaryGeometric Mean Fold Rise (GMFR) From Before Vaccination to Each Subsequent Time Point After Vaccination for SARS-CoV-2 Neutralizing Titers in Evaluable Maternal Participants

GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMFR from before vaccination to each subsequent time point after vaccination for SARS-CoV-2 neutralizing titers in evaluable maternal participants at 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery was reported in this outcome measure. Evaluable immunogenicity population included all participants who were eligible and randomized, received 2 doses of the vaccine to which they were randomized, with Dose 2 received within the predefined window (19-42 days, inclusive, after Dose 1); had at least 1 valid immunogenicity result within an appropriate window 1 month after Dose 2 (28-42 days, inclusive, after Dose 2); and had no other important protocol deviations as determined by the clinician.

Time frame:
From before dose 1 up to 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rise (GMFR) From Before Vaccination to Each Subsequent Time Point After Vaccination for SARS-CoV-2 Neutralizing Titers in Evaluable Maternal Participants
Fold riseMaternal Participants: BNT162b2 30 mcgMaternal Participants: Placebo
2 weeks after Dose 243.7 (33.9 to 56.4)1.0 (1.0 to 1.1)
1 month after Dose 225.3 (18.9 to 33.9)1.0 (1.0 to 1.0)
At delivery15.6 (12.1 to 20.1)1.0 (1.0 to 1.0)
6 months after delivery11.3 (5.0 to 25.4)—
SecondaryPercentage of Infant Participants Reporting Specific Birth Outcomes

Percentage of infant participants reporting specific birth outcomes (normal, congenital malformation/anomaly, other neonatal problems) were reported in this outcome measure.

Time frame:
At birth
Reported as:
Number · Percentage of participants
Percentage of Infant Participants Reporting Specific Birth Outcomes
Percentage of participantsInfant Participants: BNT162b2 30 mcgInfant Participants: Placebo
Normal91.6 (86.3 to 95.3)89.3 (83.6 to 93.5)
Congenital malformation/anomaly6.0 (2.9 to 10.7)3.6 (1.3 to 7.6)
Other neonatal problem1.8 (0.4 to 5.2)6.5 (3.3 to 11.4)
SecondaryPercentage of Infant Participants Reporting Adverse Events From Birth Through 1 Month of Age

An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
From birth through 1 month of age
Reported as:
Number · Percentage of participants
Percentage of Infant Participants Reporting Adverse Events From Birth Through 1 Month of Age
Percentage of participantsInfant Participants: BNT162b2 30 mcgInfant Participants: Placebo
Percentage of Infant Participants Reporting Adverse Events From Birth Through 1 Month of Age35.3 (27.8 to 43.3)37.1 (29.6 to 45.1)
SecondaryPercentage of Infant Participants Reporting Serious Adverse Events (SAE) From Birth Through 6 Months of Age

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
From birth through 6 months of age
Reported as:
Number · Percentage of participants
Percentage of Infant Participants Reporting Serious Adverse Events (SAE) From Birth Through 6 Months of Age
Percentage of participantsInfant Participants: BNT162b2 30 mcgInfant Participants: Placebo
Percentage of Infant Participants Reporting Serious Adverse Events (SAE) From Birth Through 6 Months of Age13.5 (8.5 to 19.8)15.1 (9.9 to 21.6)
SecondaryPercentage of Infant Participants Reporting Adverse Event of Special Interest (AESI) From Birth Through 6 Months of Age

Percentage of infant participants who reported AESI including major congenital anomalies and developmental delay from birth through 6 months of age were reported in this outcome measure. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
From birth through 6 months of age
Reported as:
Number · Percentage of participants
Percentage of Infant Participants Reporting Adverse Event of Special Interest (AESI) From Birth Through 6 Months of Age
Percentage of participantsInfant Participants: BNT162b2 30 mcgInfant Participants: Placebo
Percentage of Infant Participants Reporting Adverse Event of Special Interest (AESI) From Birth Through 6 Months of Age5.1 (2.2 to 9.9)1.3 (0.2 to 4.5)
SecondaryGMCs of Full-Length S-Binding IgG Levels at Birth and 6 Months of Age in Infant Participants Born to Evaluable Maternal Participants

GMCs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMCs of full-length S-binding IgG levels at birth and 6 months of age in infant participants born to evaluable maternal participants was reported in this outcome measure.

Time frame:
At birth and 6 months of age
Reported as:
Geometric mean · Units/milliliter (U/mL)
GMCs of Full-Length S-Binding IgG Levels at Birth and 6 Months of Age in Infant Participants Born to Evaluable Maternal Participants
Units/milliliter (U/mL)Infant Participants: BNT162b2 30 mcgInfant Participants: Placebo
At Birth5576.4 (4246.2 to 7323.2)19.4 (10.2 to 37.0)
6 months of age311.1 (235.8 to 410.5)22.0 (11.4 to 42.7)
SecondaryGMFR of Full-Length S-Binding IgG Levels From Birth to 6 Months of Age in Infant Participants Born to Evaluable Maternal Participants

GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMFR of full-length S-binding IgG levels from birth to 6 months of age in infant participants born to evaluable maternal participants was reported in this outcome measure.

Time frame:
From birth to 6 months of age
Reported as:
Geometric mean · Fold rise
GMFR of Full-Length S-Binding IgG Levels From Birth to 6 Months of Age in Infant Participants Born to Evaluable Maternal Participants
Fold riseInfant Participants: BNT162b2 30 mcgInfant Participants: Placebo
GMFR of Full-Length S-Binding IgG Levels From Birth to 6 Months of Age in Infant Participants Born to Evaluable Maternal Participants0.1 (0.0 to 0.1)0.6 (0.3 to 1.3)

Adverse events

Collected over Maternal participants-Local reactions/systemic events: From Day (D) 1 to 7 after dose 1 and 2; SAEs: from dose 1 on D 1 up to 6 months (M) after delivery (approx 10 M) (BNT162b2 30 mcg) and up to 1 M after delivery (approx 5 M) (placebo); placebo then BNT162b2: from Dose 3 up to 1 M after Dose 4 (approx 2 M); other AEs: from dose 1 up to 1 M after dose 2 (approx 2 M); (placebo then BNT162b2): from Dose 3 up to 1 M after Dose 4 (approx 2 M). For infants-SAEs and AESIs: from birth up to 6 M of age. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Maternal Participants: BNT162b2 30 mcg (Blinded Phase)0/161 (0%)21/161 (13%)143/161 (88.8%)
Maternal Participants: Placebo (Blinded Phase)0/163 (0%)23/163 (14.1%)119/163 (73%)
Maternal Participants: Placebo Then BNT162b2 (Unblinded Phase)0/144 (0%)0/144 (0%)21/144 (14.6%)
Infant Participants: BNT162b2 30 mcg0/156 (0%)21/156 (13.5%)29/156 (18.6%)
Infant Participants: Placebo1/159 (0.6%)24/159 (15.1%)33/159 (20.8%)
HIV Positive Maternal Participants: BNT162b2 30 mcg (Blinded Phase)0/12 (0%)2/12 (16.7%)12/12 (100%)
HIV Positive Maternal Participants: Placebo (Blinded Phase)0/10 (0%)4/10 (40%)10/10 (100%)
HIV Positive Maternal Participants: Placebo Then BNT162b2 (Unblinded Phase)0/8 (0%)0/8 (0%)1/8 (12.5%)
HIV Positive Infant Participants: BNT162b2 30 mcg1/11 (9.1%)1/11 (9.1%)1/11 (9.1%)
HIV Positive Infant Participants: Placebo0/9 (0%)2/9 (22.2%)3/9 (33.3%)
Most frequent serious events
Showing 10 of 100
Most frequent serious events
EventMaternal Participants: BNT162b2 30 mcg (Blinded Phase)Maternal Participants: Placebo (Blinded Phase)Maternal Participants: Placebo Then BNT162b2 (Unblinded Phase)Infant Participants: BNT162b2 30 mcgInfant Participants: PlaceboHIV Positive Maternal Participants: BNT162b2 30 mcg (Blinded Phase)HIV Positive Maternal Participants: Placebo (Blinded Phase)HIV Positive Maternal Participants: Placebo Then BNT162b2 (Unblinded Phase)HIV Positive Infant Participants: BNT162b2 30 mcgHIV Positive Infant Participants: Placebo
Urinary tract infectionInfections and infestations0/1611/1630/1440/1560/1590/120/100/80/111/9
Neonatal pneumoniaInfections and infestations0/1610/1630/1441/1561/1590/120/100/80/111/9
GastroenteritisInfections and infestations0/1610/1630/1440/1560/1590/120/100/80/111/9
DehydrationMetabolism and nutrition disorders0/1610/1630/1440/1560/1590/120/100/80/111/9
Superior sagittal sinus thrombosisNervous system disorders0/1610/1630/1440/1560/1590/120/100/80/111/9
Cephalo-pelvic disproportionPregnancy, puerperium and perinatal conditions1/1613/1630/1440/1560/1590/121/100/80/110/9
Fetal distress syndromePregnancy, puerperium and perinatal conditions3/1612/1630/1440/1560/1591/121/100/80/110/9
Fetal hypokinesiaPregnancy, puerperium and perinatal conditions1/1611/1630/1440/1560/1590/121/100/80/110/9
Failed trial of laborPregnancy, puerperium and perinatal conditions0/1610/1630/1440/1560/1590/121/100/80/110/9
PneumoniaInfections and infestations0/1611/1630/1440/1560/1590/120/100/81/110/9
Most frequent other events
Showing 10 of 64
Most frequent other events
EventMaternal Participants: BNT162b2 30 mcg (Blinded Phase)Maternal Participants: Placebo (Blinded Phase)Maternal Participants: Placebo Then BNT162b2 (Unblinded Phase)Infant Participants: BNT162b2 30 mcgInfant Participants: PlaceboHIV Positive Maternal Participants: BNT162b2 30 mcg (Blinded Phase)HIV Positive Maternal Participants: Placebo (Blinded Phase)HIV Positive Maternal Participants: Placebo Then BNT162b2 (Unblinded Phase)HIV Positive Infant Participants: BNT162b2 30 mcgHIV Positive Infant Participants: Placebo
Injection site pain (PAIN AT INJECTION SITE)General disorders138/16130/16313/1440/1560/15912/124/100/80/110/9
Fatigue (FATIGUE)General disorders101/16182/1630/1440/1560/1598/128/100/80/110/9
Headache (HEADACHE)Nervous system disorders85/16172/1630/1440/1560/1597/127/100/80/110/9
Arthralgia (NEW OR WORSENED JOINT PAIN)Musculoskeletal and connective tissue disorders22/16113/1630/1440/1560/1591/125/100/80/110/9
Myalgia (NEW OR WORSENED MUSCLE PAIN)Musculoskeletal and connective tissue disorders53/16126/1630/1440/1560/1595/123/100/80/110/9
Diarrhea (DIARRHEA)Gastrointestinal disorders24/16121/1630/1440/1560/1593/123/100/80/110/9
Vomiting (VOMITING)Gastrointestinal disorders18/16116/1630/1440/1560/1593/121/100/80/110/9
Chills (CHILLS)General disorders28/16110/1632/1440/1560/1591/121/100/80/110/9
HeadacheNervous system disorders2/1612/1637/1440/1560/1590/120/101/80/110/9
CoughRespiratory, thoracic and mediastinal disorders0/1610/1630/1440/1560/1590/120/101/80/110/9

Baseline characteristics

For maternal participants, safety population included all randomized participants who received at least 1 dose of the study intervention. For infant participants, safety population included all infant participants born to maternal participants who received at least 1 dose of the study intervention.

Age, Customized
Age, Customized(Participants)Maternal Participants: BNT162b2 30 mcgMaternal Participants: Placebo Then BNT162b2 30 mcgInfant Participants: BNT162b2 30 mcgInfant Participants: PlaceboTotal
Less than (<) 18 years00167168335
Greater than or equal to (>=) 18 and <= 45 years17317300346
Sex: Female, Male
Sex: Female, Male(Participants)Maternal Participants: BNT162b2 30 mcgMaternal Participants: Placebo Then BNT162b2 30 mcgInfant Participants: BNT162b2 30 mcgInfant Participants: PlaceboTotal
Female1731738573504
Male008295177
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Maternal Participants: BNT162b2 30 mcgMaternal Participants: Placebo Then BNT162b2 30 mcgInfant Participants: BNT162b2 30 mcgInfant Participants: PlaceboTotal
Hispanic or Latino70636560258
Not Hispanic or Latino10311098104415
Unknown or Not Reported00448
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Maternal Participants: BNT162b2 30 mcgMaternal Participants: Placebo Then BNT162b2 30 mcgInfant Participants: BNT162b2 30 mcgInfant Participants: PlaceboTotal
American Indian or Alaska Native11125
Asian593724
Native Hawaiian or Other Pacific Islander01001
Black or African American47434040170
White117118115104454
More than one race10067
Unknown or Not Reported218920
08

Study locations

90 sites
  • Children's of Alabama
    Birmingham, Alabama 35233, United States
  • University of Alabama at Birmingham Women & Infant Center
    Birmingham, Alabama 35233, United States
  • University of Alabama at Birmingham/Center for Women's Reproductive Health
    Birmingham, Alabama 35233, United States
  • Velocity Clinical Research, Gulfport
    Mobile, Alabama 36608, United States
  • Arrowhead Hospital
    Glendale, Arizona 85308, United States
  • Abrazo West Campus Hospital
    Goodyear, Arizona 85395, United States
  • St. Joseph Hospital
    Phoenix, Arizona 85013, United States
  • MedPharmics, LLC
    Phoenix, Arizona 85015, United States
  • Matrix Clinical Research.
    Huntington Park, California 90255, United States
  • Matrix Clinical Research
    Huntington Park, California 90255, United States
  • Chemidox Clinical Trials Inc.
    Lancaster, California 93534, United States
  • East LA Doctors Hospital
    Los Angeles, California 90023, United States
  • Matrix Clinical Research
    Los Angeles, California 90057, United States
  • Axcess Medical Research
    Loxahatchee Groves, Florida 33470, United States
  • Idaho Falls Pediatrics
    Ammon, Idaho 83406, United States
  • Bingham Memorial Hospital
    Blackfoot, Idaho 83221, United States
  • Idaho Falls Pediatrics
    Idaho Falls, Idaho 83402, United States
  • Clinical Research Prime
    Idaho Falls, Idaho 83404, United States
  • Eastern Idaho Regional Medical Center
    Idaho Falls, Idaho 83404, United States
  • Mountain View Hospital
    Idaho Falls, Idaho 83404, United States
  • Covenant Healthcare
    Saginaw, Michigan 48604, United States
  • Saginaw Valley Medical Research Group, LLC
    Saginaw, Michigan 48604, United States
  • Community Hospital of Anaconda
    Anaconda, Montana 59711, United States
  • Boeson Research (BUT)
    Butte, Montana 59701, United States
  • SCL St. James Healthcare Hospital
    Butte, Montana 59701, United States
  • Marcus Daly Memorial Hospital
    Hamilton, Montana 59840, United States
  • Providence St. Patrick Hospital
    Missoula, Montana 59802, United States
  • The Birth Center
    Missoula, Montana 59803, United States
  • Boeson Research
    Missoula, Montana 59804, United States
  • Community Medical Center
    Missoula, Montana 59804, United States
  • Community Physicians Group-Maternal Fetal Medicine
    Missoula, Montana 59804, United States
  • St. Luke Community Healthcare Hospital
    Ronan, Montana 59864, United States
  • Meridian Clinical Research, LLC
    Hastings, Nebraska 68901, United States
  • Meridian Clinical Research, LLC
    Norfolk, Nebraska 68701, United States
  • Allegheny Health and Wellness Pavilion
    Erie, Pennsylvania 16506, United States
  • OBGYN Associates of Erie
    Erie, Pennsylvania 16507, United States
  • Central Erie Primary Care
    Erie, Pennsylvania 16508, United States
  • Liberty Family Practice
    Erie, Pennsylvania 16508, United States
  • Saint Vincent Hospital
    Erie, Pennsylvania 16544, United States
  • St. David's Medical Center
    Austin, Texas 78705, United States
  • Tekton Research, Inc.
    Austin, Texas 78705, United States
  • Tekton Research, Inc.
    Austin, Texas 78745, United States
  • Texas Health Harris Methodist Hospital Hurst-Euless-Bedford
    Bedford, Texas 76022, United States
  • Ventavia Research Group LLC
    Dallas, Texas 75231, United States
  • DHR Health Institute for Research and Development
    Edinburg, Texas 78539, United States
  • 8th Avenue Obstetrics & Gynecology
    Fort Worth, Texas 76104, United States
  • Baylor Scott & White All Saints Medical Center
    Fort Worth, Texas 76104, United States
  • Ventavia Research Group, LLC
    Fort Worth, Texas 76104, United States
  • Dr. Ruben Aleman & Associates
    McAllen, Texas 78504, United States
  • Ventavia Research Group, LLC
    Plano, Texas 75093, United States
  • Ventavia Research Group, LLC
    Weatherford, Texas 76086, United States
  • Weatherford OBGYN
    Weatherford, Texas 76086, United States
  • University of Utah Hospital
    Salt Lake City, Utah 84132, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • The Group for Women- MAWC
    Norfolk, Virginia 23502, United States
  • Tidewater Physicians for Women- MAWC
    Norfolk, Virginia 23502, United States
  • Faculdade de Medicina da Universidade Federal de Minas Gerais
    Belo Horizonte, Minas Gerais 30.130-100, Brazil
  • Hospital das Clínicas da Universidade Federal de Minas Gerais
    Belo Horizonte, Minas Gerais 30130-100, Brazil
  • Hospital Santa Casa de Misericordia de Sorocaba
    Sorocaba, SAO Paulo 18013-000, Brazil
  • Unimed Sorocaba-Hospital Dr. Miguel Soeiro (HMS)
    Sorocaba, SAO Paulo 18052-210, Brazil
  • Clinica de Alergia Martti Antila S/S Ltda./ CMPC - Consultoria Medica e Pesquisa Clinica
    Sorocaba, SP 18040-425, Brazil
  • HMU SBC - Hospital Municipal Universitário de São Bernardo
    São Bernardo do Campo, SÃO Paulo 09624-000, Brazil
  • CEMEC - Centro Multidisciplinar de Estudos Clínicos
    São Bernardo do Campo, SÃO Paulo 09715 - 090, Brazil
  • WorthWhile Clinical Trials
    Benoni, Gauteng 1500, South Africa
  • Wits Reproductive Health and HIV Institute (Wits RHI) Shandukani Research Centre
    Johannesburg, Gauteng 2001, South Africa
  • Botho Ke Bontle Health Services
    Pretoria, Gauteng 0122, South Africa
  • Vaccines and Infectious Diseases Analytics (VIDA)
    Soweto, Gauteng 2013, South Africa
  • Dr Tobias de Villiers
    Cape Town, Western CAPE 7500, South Africa
  • Tiervlei Trial Centre CC
    Cape Town, Western CAPE 7530, South Africa
  • Hospital Universitari Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
  • Hospital Sant Joan de Deu
    Esplugues de Llobregat, Barcelona 08950, Spain
  • Hospital Universitario HM Monteprincipe
    Boadilla del Monte, Madrid 28660, Spain
  • Hospital de Antequera
    Antequera, Malaga 29200, Spain
  • Hospital Quironsalud Barcelona
    Barcelona, 08023, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08041, Spain
  • Clinica Diagonal
    Barcelona, 08950, Spain
  • Hospital Madrid Puerta del Sur Mostoles
    Mostoles, 28938, Spain
  • Instituto Hispalense de Pediatria- IHP1
    Sevilla, 41012, Spain
  • Hospital Materno-Infantil Quirón
    Sevilla, 41013, Spain
  • Servicio de Ginecología del Hospital Quirón Salud Sagrado Corazón
    Sevilla, 41013, Spain
  • Hampshire Research Hub, Royal South Hants Hospital
    Southampton, Hampshire SO14 0YG, United Kingdom
  • University Hospital Southampton NHS Foundation Trust
    Southampton, Hampshire SO16 6YD, United Kingdom
  • Medway NHS Foundation Trust
    Gillingham, Kent ME7 5NY, United Kingdom
  • Leeds Teaching Hospitals NHS Trust
    Leeds, LS9 7TF, United Kingdom
  • University College London Hospitals
    London, NW1 2PG, United Kingdom
  • University College London Hospitals
    London, W1T 7HA, United Kingdom
  • University College London Hospitals
    London, WC1E 6EB, United Kingdom
  • Royal Victoria Infirmary
    Newcastle upon Tyne, NE1 4LP, United Kingdom
  • John Radcliffe Hospital
    Oxford, OX3 9DU, United Kingdom
09

References and documents

Publications

  • Nana M, Hodson K, Lucas N, Camporota L, Knight M, Nelson-Piercy C. Diagnosis and management of covid-19 in pregnancy. BMJ. 2022 Apr 26;377:e069739. doi: 10.1136/bmj-2021-069739. PubMed 35473709 ↗
  • Mohapatra S, Ananda P, Tripathy S. Pharmacological consideration of COVID-19 infection and vaccines in pregnancy. J Chin Med Assoc. 2022 May 1;85(5):537-542. doi: 10.1097/JCMA.0000000000000712. Epub 2022 May 2. PubMed 35316227 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Jul 2022, 16 months.

Results were first posted in Dec 2024, 2 years 4 months after primary completion.

Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 16 months is above that.

Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2021
First posted
Feb 15, 2021
StartActual
Feb 16, 2021
Primary completionActual
Jul 15, 2022
CompletionActual
Jul 15, 2022
Results first posted
Dec 6, 2024
Last update
Dec 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04754594
Lead sponsor
BioNTech SE
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Feb 15, 2021
Start date
Feb 16, 2021
Primary completion
Jul 15, 2022
Completion
Jul 15, 2022
Results posted
Dec 6, 2024
Last update
Dec 6, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BNT162 Vaccine

Start the discussion